Clinical Trials
12 trialsNCT03132922 2026-06-04
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Phase 1 Active not recruiting
NCT03935893 2026-06-01
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Phase 2 Active not recruiting
NCT06904365 2026-05-18
OvAR-Y
Washington University School of Medicine
Active not recruiting
NCT04704661 2026-05-13
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT00582647 2026-01-15
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
Memorial Sloan Kettering Cancer Center
Active not recruiting
NCT05075993 2025-12-26
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05238883 2025-11-21
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
Phase 1 Active not recruiting
NCT05864144 2025-08-15
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Phase 1/2 Active not recruiting
NCT04140526 2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT05179824 2025-05-06
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Active not recruiting
NCT04511871 2024-10-28
A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
Shanghai PerHum Therapeutics Co., Ltd.
Phase 1 Active not recruiting
NCT04584008 2024-10-15
VISIONARY
Peking University
Phase NA Active not recruiting